4320 Forest Park Avenue
Tel: 314-932-4032 X317
About Indalo Therapeutics
Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space.
Founder and CMO: Williamson Z. Bradford, M.D., Ph.D.
Founder and CSO: Scott D. Seiwert, Ph.D.
Sr. VP of Pharmaceutical Development: Ramachandran Radhakrishnan, Ph.D.
Sr. VP of Translational Science: Karl Kossen, Ph.D.
VP and Head of Business Operations: George H. Capps, M.S., M.B.A.
4 articles with Indalo Therapeutics
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Financial terms of the deal were not disclosed.